Sciwind has two Western partners for its obesity drug, but is open to more
先为达生物肥胖症药物已有两家西方合作伙伴，但仍愿寻求更多合作

Sciwind Biosciences has already licensed its GLP-1 obesity drug ecnoglutide twice over — to Pfizer and Verdiva Bio — but it is not done yet.
先为达生物旗下GLP-1减重药物埃诺格鲁肽已先后授权给辉瑞和Verdiva Bio，但这家公司并未就此收手。